Jane S. Ricciuti, RPh, MS


June 03, 2004

In This Article

Urologic Agents

(finasteride) Tablets

Manufacturer: Merck

Drug Approval Classification: Supplemental New Drug Application (Approval Date: 04/12/04)

New Indication: This supplemental NDA provides for the use of Proscar (finasteride) administered in combination with the alpha-blocker doxazosin and is indicated to reduce the risk of symptomatic progression of benign prostatic hyperplasia (a confirmed > 4-point increase in AUA symptom score).

Proscar (finasteride) Tablets Labeling

Proscar (finasteride) Tablets